Saama Expands Collaboration with Pfizer to Expedite Clinical Research

Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, has entered a newly expanded, multi-year agreement with Pfizer to help expedite clinical research.
 
The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer partnered to automate Pfizer’s data review processes with artificial intelligence (AI). The result of that initial collaboration was Smart Data Quality (SDQ), which significantly cut down the time to database lock. With this new agreement, Pfizer will continue to scale SDQ to help streamline and accelerate its data review processes across its broader portfolio of global studies.
 
“Our initial collaboration with Pfizer for its COVID-19 vaccine demonstrated the unprecedented power of our AI-enabled technology platform to improve and accelerate the clinical trial process, and ultimately, its ability to help bring treatments to patients faster,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama. “The opportunity to now scale across more of the Pfizer portfolio underscores the evidence-based potential of Saama’s one-of-a-kind platform to fundamentally change the way drug development is done to benefit more people around the world.”
 
Not limited to SDQ, the new agreement expands the existing relationship to help Pfizer to accelerate regulatory submissions across its portfolio using Saama’s new advanced Biometrics Research and Analysis Information Network.
 
Pfizer will now have the potential to reduce regulatory submission timelines across its global portfolio, as this next-generation solution streamlines statistical programming and biostatistics workflows, digitizes study specifications, and generates submission-ready tables, listings, and figures (TLF) artifacts. It will also set the stage for continuing automation and innovation to further accelerate future trial submissions.

More Pfizer News